



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 021167-000700US

U.S. Patent and Trademark Office
Box SEQUENCE
P.O. Box 2327
Arlington, VA 22202

On Feb. 26/2003

TOWNSEND and TOWNSEND and CREW LLP

By: Jo Ann Dallara

RECEIVED
MAR 26 2003
TECH CENTER 1600/2900

21/a
6/10/03
4303

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

BALINT and HER

Application No.: 09/526,106

Filed: March 15, 2000

For: INTERACTION-ACTIVATED
PROTEINS

Examiner: Friend, Tomas H. F.

Art Unit: 1639

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

U.S. Patent and Trademark Office
Box SEQUENCE
P.O. Box 2327
Arlington, VA 22202

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Communication mailed December 31, 2002, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.